SunTrust Robinson Humphrey Initiates Coverage On Genmab with Buy Rating, Announces $28 Price Target

SunTrust Robinson Humphrey analyst Asthika Goonewardene initiates coverage on Genmab (NASDAQ:GMAB) with a Buy rating and a $28 price target.

Benzinga · 01/13/2020 13:52

SunTrust Robinson Humphrey analyst Asthika Goonewardene initiates coverage on Genmab (NASDAQ:GMAB) with a Buy rating and a $28 price target.